Skip to main content

Table 3 Characteristics of participants at study entry, with or without contrast-induced nephropathy (CIN)

From: The impact of N-acetylcysteine and ascorbic acid in contrast-induced nephropathy in critical care patients: an open-label randomized controlled study

  CIN (n = 21) No CIN (n = 103) P value
Age (years) 54 (4.90) 50.80 (2.12) 0.55
Male gender, n (%) 17 (80.95) 79 (76.69) 0.78
Weight (Kg) 73.23 (2.32) 68.15 (1.34) 0.68
Height (cm) 164 169 0.57
BMI (Kg/m2) 27 26 0.80
APACHE II score 14.95 (1.79) 13.68 (0.69) 0.51
SOFA score 6.53 (0.8) 5.69 (0.34) 0.34
Category of admission
 Medical, n (%) 9 (42.86) 44 (42.72) 0.15
 Surgical, n (%) 2 (9.52) 27 (26.21) 0.15
 Neurosurgical, n (%) 10 (47.62) 32 (31.07) 0.20
Comorbidities
 Diabetes, n (%) 2 (9.52) 10 (9.71) 0.68
 Hypertension, n (%) 4 (19.05) 32 (31.07) 0.57
 Cardiovascular, n (%) 3 (14.29) 11 (10.68) 0.70
 Cirrhosis, n (%) 1 (4.76) 0 0.16
 Renal disease, n (%) 1 (4.76) 6 (5.83) 0.41
 Sepsis, n (%) 8 (38.10) 35 (33.98) 0.80
 COPD, n (%) 3 (14.28) 16(15.53) 1.00
 Charlson index score 2.32 (0.57) 2.10 (0.24) 0.70
Serum creatinine (mg/dl) 0.87 (0.08) 0.96 (0,07) 0.39
Serum cystatin-C (mg/L) 1.34 (0.23) 0.98 (0.05) 0.14
Serum urea (mg/dl, median) 55 (8.34) 44 (3.82) 0.18
Serum urea/creatinine 73.19 (6.3) 58.65 (2.5) 0.01
Fluid balance/24 h (ml) 1462 (169) 1058 (338.1) 0.30
Vasoactive therapy, n (%) 9 (42.86) 45 (43.69) 0.13
Noradrenaline dose, γ 0.1 (0.05) 0.06 (0.01) 0.20
Mechanical ventilation, n (%) 15 (71.43) 51 (49.51) 0.09
Diuretic therapy, n (%) 1 (4.76) 19 (18.45) 0.19
ACEi or ARBs, n (%) 7 (33.33) 20 (19.42) 0.19
Nephrotoxic medications, n (%) 19 (90.48) 68 (66.02) 0.03
Volume of contrast agent (ml) 126.3 (5.88) 122.2 (2.77) 0.53
Multiple studies, n (%) 6 (28.57) 13 (12.62) 0.09
Length of ICU stay (days, median) 29 (3.97) 25 (7.85) 0.80
Length of ICU stay before entering the study (days) 20.71 (4.4) 18.15 (2.7) 0.68
ICU mortality, n (%) 6 (28.57) 20 (19.42) 0.38
RRT 10 days post contrast agent, n (%) 3 (14.28) 4 (4.85) 0.09
Total duration on RRT (h) 47.67 (17.32) 49.25 (9.29) 0.93
  1. Data presented as mean (SE) unless otherwise indicated. Nephrotoxic drugs included at least one of the following: aminoglycosides, amphotericin, colimycin, vancomycin, teicoplanin or any non-steroidal anti-inflammatory drug
  2. CIN contrast-induced nephropathy, BMI body mass index, APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment score, COPD chronic obstructive pulmonary disease, ACEi angiotensin converting enzyme inhibitor, ARBs angiotensin II receptor blockers, RRT renal replacement therapy